JP2021523114A - リンパ腫の治療方法 - Google Patents

リンパ腫の治療方法 Download PDF

Info

Publication number
JP2021523114A
JP2021523114A JP2020561635A JP2020561635A JP2021523114A JP 2021523114 A JP2021523114 A JP 2021523114A JP 2020561635 A JP2020561635 A JP 2020561635A JP 2020561635 A JP2020561635 A JP 2020561635A JP 2021523114 A JP2021523114 A JP 2021523114A
Authority
JP
Japan
Prior art keywords
lymphoma
cerduratinib
cell lymphoma
patient
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561635A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019213589A5 (https=
JP2021523114A5 (https=
Inventor
グレゴリー コフィー，
グレゴリー コフィー，
マシュー ビレル，
マシュー ビレル，
パメラ ビー． コンリー，
パメラ ビー． コンリー，
ジョン ティー． カーナット，
ジョン ティー． カーナット，
アンジャリ パンディー，
アンジャリ パンディー，
アンドリュー スティール，
アンドリュー スティール，
グレン マイケルソン，
グレン マイケルソン，
Original Assignee
ポートラ ファーマシューティカルズ， インコーポレイテッド
ポートラ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポートラ ファーマシューティカルズ， インコーポレイテッド, ポートラ ファーマシューティカルズ， インコーポレイテッド filed Critical ポートラ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2021523114A publication Critical patent/JP2021523114A/ja
Publication of JPWO2019213589A5 publication Critical patent/JPWO2019213589A5/ja
Publication of JP2021523114A5 publication Critical patent/JP2021523114A5/ja
Priority to JP2024001279A priority Critical patent/JP2024024093A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020561635A 2018-05-04 2019-05-03 リンパ腫の治療方法 Pending JP2021523114A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001279A JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862667249P 2018-05-04 2018-05-04
US62/667,249 2018-05-04
US201862678934P 2018-05-31 2018-05-31
US62/678,934 2018-05-31
US201862736047P 2018-09-25 2018-09-25
US62/736,047 2018-09-25
PCT/US2019/030690 WO2019213589A1 (en) 2018-05-04 2019-05-03 Methods for treating lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001279A Division JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Publications (3)

Publication Number Publication Date
JP2021523114A true JP2021523114A (ja) 2021-09-02
JPWO2019213589A5 JPWO2019213589A5 (https=) 2022-05-18
JP2021523114A5 JP2021523114A5 (https=) 2022-05-18

Family

ID=66554509

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561635A Pending JP2021523114A (ja) 2018-05-04 2019-05-03 リンパ腫の治療方法
JP2024001279A Pending JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001279A Pending JP2024024093A (ja) 2018-05-04 2024-01-09 リンパ腫の治療方法

Country Status (11)

Country Link
US (3) US11266645B2 (https=)
EP (1) EP3787628A1 (https=)
JP (2) JP2021523114A (https=)
KR (1) KR20210003789A (https=)
CN (1) CN112074271B (https=)
AU (1) AU2019262644A1 (https=)
BR (1) BR112020022430A2 (https=)
CA (1) CA3098012A1 (https=)
MX (1) MX2020011817A (https=)
TW (1) TW202014190A (https=)
WO (1) WO2019213589A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788035B1 (en) 2018-05-04 2024-08-07 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2023091785A1 (en) * 2021-11-22 2023-05-25 Secura Bio, Inc. Methods for treating peripheral t-cell lymphoma
CN114306606B (zh) * 2021-11-29 2023-05-26 江苏省人民医院（南京医科大学第一附属医院） cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用
CN115177620A (zh) * 2022-07-18 2022-10-14 厦门大学附属第一医院 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
WO2024115935A1 (en) * 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
CN117427166B (zh) * 2023-09-25 2024-09-10 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Csf1r抑制剂用于制备nk/t细胞淋巴瘤治疗药物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196385A1 (en) * 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
EP1845778A2 (en) 2005-01-10 2007-10-24 University Of Virginia Patent Foundation Synthesis of inhibitors of p90rsk
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
AU2016363005A1 (en) * 2015-12-04 2018-07-05 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196385A1 (en) * 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. Vol.130(Suppl_1):2782, JPN6023012254, 2017, pages 1 - 3, ISSN: 0005022115 *
PORTOLA PHARMACEUTICALS PRESENTS INTERIM PHASE 2A SAFETY AND EFFICACY DATA FOR CERDULATINIB AT THE I, JPN6023012255, 15 June 2017 (2017-06-15), ISSN: 0005253275 *

Also Published As

Publication number Publication date
US20220233533A1 (en) 2022-07-28
US11266645B2 (en) 2022-03-08
AU2019262644A1 (en) 2020-11-12
CN112074271A (zh) 2020-12-11
US20250213562A1 (en) 2025-07-03
KR20210003789A (ko) 2021-01-12
JP2024024093A (ja) 2024-02-21
US20200061060A1 (en) 2020-02-27
TW202014190A (zh) 2020-04-16
MX2020011817A (es) 2021-02-26
EP3787628A1 (en) 2021-03-10
CA3098012A1 (en) 2019-11-07
CN112074271B (zh) 2023-10-20
WO2019213589A1 (en) 2019-11-07
BR112020022430A2 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
US20250213562A1 (en) Methods for treating lymphoma
JP7651018B2 (ja) ジアシルグリセロールキナーゼ調節化合物
CN113226324A (zh) 作为a2a抑制剂的硫代氨基甲酸酯衍生物、其药物组合物以及与抗癌剂的组合
TWI854244B (zh) 二醯基甘油激酶調節化合物
US20230301979A1 (en) Combinations for the treatment of cancer
US20230346772A1 (en) Combination treatments for waldenstrom's macroglobulinemia
CN107683139A (zh) 用于治疗b细胞恶性肿瘤的赛度替尼
EP2922546A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
TWI839921B (zh) Cd73化合物
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
RU2784243C2 (ru) Способы лечения лимфомы
WO2024097940A1 (en) Therapy for the treatment of cancer
US20240050432A1 (en) Eganelisib for use in the treatment of pd-l1 negative cancer
JP2023529313A (ja) 低悪性度ｂ細胞リンパ腫における循環ｂ細胞亜集団
WO2025193763A1 (en) Method for increasing survival in patients with cancer
HK40113696A (zh) Cd73化合物
EA053105B1 (ru) Соединения cd73
HK40105875A (zh) 二酰基甘油激酶调节化合物
HK40112835A (zh) 二酰基甘油激酶调节化合物
HK40107638A (zh) 二酰基甘油激酶调节化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240117

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240209